Key Considerations for the Pre-clinical Development of Therapeutic Innovations

This presentation provides a high-level look at the critical milestones and timelines for translating your therapeutic innovation to clinical reality, paying special attention to the unique impact clinical context and regulatory considerations have on your development pathway. Hear from therapeutic innovator Mukesh Nyati, Ph.D., as he discusses the preclinical development of a novel small molecule that selectively inhibits dimerization of active EGFR as a therapy for TKI resistant lung cancer.